Source: ClinicalTrials.gov
A Study of Acalabrutinib vs Investigator's Choice of Idelalisib Plus Rituximab or Bendamustine Plus Rituximab in R/R CLL
View on ClinicalTrials.govCitation record
- Study start
- 2017-02-02
- NCT number
- NCT02970318
- Phase
- Phase3
- Overall status
- Active Not Recruiting
- Study type
- Interventional
- Lead sponsor
- Acerta Pharma BV
- Enrollment
- 310 participants
- Conditions
- Chronic Lymphocytic Leukemia
- Interventions
- Acalabrutinib (ACP-196) (Drug) · Rituximab (Drug) · Idelalisib (Drug) · Bendamustine (Drug)
- Last updated at source
- 23 Oct 2026
- Original source
- https://clinicaltrials.gov/study/NCT02970318
This page reproduces citation metadata only. Inclusion in the Avion Science research library does not imply endorsement and does not establish the safety, efficacy or intended use of any Avion Science compound. Refer to the original record for complete study information.